Previous studies have identified cyclophilin inhibition as a promising therapeutic avenue for the prevention of HCC in mice, both in the context of NAFLD/NASH [11, 12, 20] and viral hepatitis [14, 21, 22]. Here, PPIB is linked to metabolic dysfunction-associated steatotic liver disease.